top of page

For all cataract surgeons managing glaucoma patients

The world’s first, IOL-mounted, controlled release drug delivery platform capable of delivering multiple years of therapy


Targeting 3-year delivery of bimatoprost to treat glaucoma in patients undergoing cataract surgery

Dual pads securely attached to each haptic are designed to elute treatment continuously for multiple years. 

The SpyGlass Drug Delivery Platform has not been approved by FDA for any use


Directly addressing an unmet need

Patient non-adherence to their glaucoma medication can lead to complications, disease progression and vision loss. Methods of drug delivery independent of patient behavior is an industry-wide need.


Millions of glaucoma patients undergo cataract surgery each year



Explore the pioneering technology behind the SpyGlass Drug Delivery Platform


Designed to deliver multiple drugs to address additional ophthalmic indications


The device you know coupled with treatment you trust. All within the same procedure you know by heart.

The SpyGlass Drug Delivery Platform is Implanted with the IOL into the capsular bag using surgical techniques identical to standard cataract procedures. 

Intraocular drug delivery that lasts

Learn more about SpyGlass Pharma 


SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases

SpyGlass Pharma, a privately-held ophthalmic therapeutics company, announced today closing $90 million in Series C financing. The financing, which was led by RA Capital Management alongside existing investors New Enterprise Associates (“NEA”) and Vensana Capital, as well as new investors Samsara BioCapital and Vertex Ventures HC, will enable the company to conduct multiple US clinical trials of SpyGlass’ innovative drug delivery platform. (View full press release)

bottom of page